Anti-coronavirus vaccine will be available in 90 days

ISLAMABAD: Israeli scientists have claimed to develop anti-coronavirus vaccine which will be available in 90 days after security tests as they will produce it during next 8-10 weeks.

An oral vaccine for the coronavirus is under works and is expected to be available within 90 days after tests have been conducted. It has been reported by Israeli Daily Mail.

The scientists in Israel have been working on a cure for the viral infection, that has claimed over 3000 lives across the world. Israeli officials have expressed hopes that the "breakthrough" will help in dealing with the outbreak.

In a statement on the MIGAL Galilee Research Institute's website, Israel’s Minister of Science and Technology Ofir Akunis, said, "Congratulations to MIGAL on this exciting breakthrough. I am confident that there will be further rapid progress, enabling us to provide a needed response to the grave global coronavirus threat.” The researchers and scientists at the institute identified a possible vaccine for coronavirus as a by-product, while working on the development of a vaccine against IBV (Infectious Bronchitis Virus), a disease that affects poultry.

The institute has made required genetic adjustments to adapt the IBV vaccine for the treatment of COVID-19, the human strain of the coronavirus. Work to achieve the necessary safety approvals that will enable in-vivo testing and the initiation of production of a vaccine to counter the coronavirus epidemic, is underway, the statement noted.

David Zigdon, CEO of MIGAL Galilee Research Institute said, “Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next 8-10 weeks, and to achieve safety approval in 90 days.”

This, he added, will be an oral vaccine, making it particularly accessible to the general public. “We are currently in intensive discussions with potential partners that can help accelerate the in-human trials phase and expedite the completion of final product development and regulatory activities,” Zigdon said.